Compare RCG & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCG | BCTX |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0M | 18.5M |
| IPO Year | N/A | N/A |
| Metric | RCG | BCTX |
|---|---|---|
| Price | $2.57 | $12.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 5.9K | ★ 48.2K |
| Earning Date | 01-01-0001 | 12-19-2025 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.52 | $6.00 |
| 52 Week High | $1.90 | $190.50 |
| Indicator | RCG | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.85 | 62.59 |
| Support Level | $2.50 | $9.25 |
| Resistance Level | $2.60 | $13.00 |
| Average True Range (ATR) | 0.07 | 0.98 |
| MACD | -0.01 | 0.47 |
| Stochastic Oscillator | 48.00 | 88.88 |
RENN Fund Inc is active in the financial services domain. It is a a registered, non-diversified, closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, oil and gas, medical chemicals, botanical products, etc.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.